4-HO-DALT

4-HO-DALT
Clinical data
Other names	4-Hydroxy-N,N-diallyltryptamine; 4-Hydroxy-DALT; 4-OH-DALT; Dalocin
Drug class	Serotonin receptor agonist; Serotonergic psychedelic; Hallucinogen
ATC code	None;
Identifiers
	IUPAC name 3-[2-[bis(prop-2-enyl)amino]ethyl]-1H-indol-4-ol;
CAS Number	2173386-70-2;
PubChem CID	119026031;
ChemSpider	52085332;
UNII	44YV9DEA7I;
CompTox Dashboard (EPA)	DTXSID101342026 ;
Chemical and physical data
Formula	C16H20N2O
Molar mass	256.349 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C=CCN(CCC1=CNC2=C1C(=CC=C2)O)CC=C;
	InChI InChI=1S/C16H20N2O/c1-3-9-18(10-4-2)11-8-13-12-17-14-6-5-7-15(19)16(13)14/h3-7,12,17,19H,1-2,8-11H2; Key:JVIWQWJXRKVJTA-UHFFFAOYSA-N;

4-HO-DALT, also known as 4-hydroxy-N,N-diallyltryptamine or as dalocin, is a serotonin receptor agonist and serotonergic psychedelic of the tryptamine and 4-hydroxytryptamine families.

It binds to many of the serotonin receptors, including the serotonin 5-HT_2A receptor, as well as other targets. The drug acts as a potent full agonist of the serotonin 5-HT_2A and 5-HT_2B receptors, whereas it showed 60-fold lower potency as an agonist of the serotonin 5-HT_2C receptor compared to the serotonin 5-HT_2A receptor. It produces the head-twitch response, a behavioral proxy of psychedelic-like effects, in rodents.

4-HO-DALT was first described in the literature by Alexander Shulgin in TiHKAL in 1997. Subsequently, it was further described in 2017 and thereafter.